表紙
市場調査レポート

左心室機能不全 : パイプライン分析

Left Ventricular Dysfunction - Pipeline Review, H1 2016

発行 Global Markets Direct 商品コード 246004
出版日 ページ情報 英文 56 Pages
即納可能
価格
本日の銀行送金レート: 1USD=105.69円で換算しております。
Back to Top
左心室機能不全 : パイプライン分析 Left Ventricular Dysfunction - Pipeline Review, H1 2016
出版日: 2016年02月24日 ページ情報: 英文 56 Pages
概要

左心室機能不全(LVD)や、それに続けて起こる鬱血性心不全(CHF)は、様々な心疾患の最終的な要因となることの多い疾患です。冠動脈の閉塞や虚血性心疾患が、心不全の原因の大半を占めており、しばしば急性/陳旧性心筋梗塞と関連付けられています。その他の原因として、心筋症や高血圧、その他の様々な要因(弁膜症、心筋炎など)が挙げられます。この疾患は通常、心不全や心筋梗塞、その他の心血管合併症へとつながっています。診断は、駆出率の低下率や、左室壁の可動性の低下レベルを計る形で実施されます。

当レポートでは、世界各国での左心室機能不全治療用のパイプライン製品の開発状況について分析し、パイプライン製品の最新動向や、治験の各段階にある製品の一覧、主要企業のプロファイル、主な薬剤の概要(製品概要、機能メカニズム、研究開発(R&D)の進展状況)、最新の業界動向などを調査して、その結果を概略以下の構成でお届けします。

イントロダクション

  • 分析範囲

左心室機能不全の概要

治療薬の開発

  • 左心室機能不全向けパイプライン製品:概要
  • 左心室機能不全向けパイプライン製品:比較分析

各企業で開発中の左心室機能不全治療薬

大学/研究機関で研究中の左心室機能不全治療薬

パイプライン製品の概略

  • 後期段階の製品
  • 治験段階の製品
  • 初期段階の製品

左心室機能不全治療薬:開発中の製品の一覧(企業別)

左心室機能不全治療薬:研究中の製品の一覧(大学/研究機関別)

左心室機能不全治療薬の開発に従事している企業

  • Acorda Therapeutics, Inc.
  • Amgen Inc.
  • Bayer AG
  • Innopharmax Inc.
  • RedHill Biopharma Ltd.
  • TiGenix NV

左心室機能不全:治療薬の評価

  • 単剤治療薬の場合
  • 標的別
  • 機能メカニズム別
  • 投与方法別
  • 分子の種類別

薬剤のプロファイル

  • BAY-1142524
  • CAP-1001
  • CAP-1002
  • carvedilol CR
  • carvedilol CR
  • cimaglermin alfa
  • CTX-101
  • omecamtiv mecarbil

左心室機能不全治療薬:最新パイプライン動向

左心室機能不全治療薬:開発が休止状態の製品

左心室機能不全治療薬:開発が中止された製品

左心室機能不全関連製品の開発のマイルストーン

  • 注目すべき最新動向・プレスリリース

付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC7554IDB

Summary

Global Markets Direct's, 'Left Ventricular Dysfunction - Pipeline Review, H1 2016', provides an overview of the Left Ventricular Dysfunction pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Left Ventricular Dysfunction, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Left Ventricular Dysfunction and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Left Ventricular Dysfunction
  • The report reviews pipeline therapeutics for Left Ventricular Dysfunction by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Left Ventricular Dysfunction therapeutics and enlists all their major and minor projects
  • The report assesses Left Ventricular Dysfunction therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Left Ventricular Dysfunction

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Left Ventricular Dysfunction
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Left Ventricular Dysfunction pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Left Ventricular Dysfunction Overview
  • Therapeutics Development
    • Pipeline Products for Left Ventricular Dysfunction - Overview
  • Left Ventricular Dysfunction - Therapeutics under Development by Companies
  • Left Ventricular Dysfunction - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Left Ventricular Dysfunction - Products under Development by Companies
  • Left Ventricular Dysfunction - Companies Involved in Therapeutics Development
    • Amgen Inc.
    • Bayer AG
    • Capricor Therapeutics, Inc.
    • Innopharmax Inc.
    • RedHill Biopharma Ltd.
    • TiGenix NV
  • Left Ventricular Dysfunction - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • BAY-1142524 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CAP-1001 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CAP-1002 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • carvedilol CR - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • carvedilol phosphate CR - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CTX-101 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • omecamtiv mecarbil MR - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Left Ventricular Dysfunction - Recent Pipeline Updates
  • Left Ventricular Dysfunction - Dormant Projects
  • Left Ventricular Dysfunction - Discontinued Products
  • Left Ventricular Dysfunction - Product Development Milestones
    • Featured News & Press Releases
      • Aug 27, 2013: Amgen to Highlight New Data at Upcoming ESC Congress 2013
      • Jun 18, 2013: Cytokinetics Announces Presentation Of Results From Phase IIb Clinical Trial Of Omecamtiv Mecarbil At ESC Congress 2013
      • Feb 19, 2013: RedHill Biopharma Announces Notice Of Allowance From US Patent And Trademark Office For Cardio Drug RHB-101
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Left Ventricular Dysfunction, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Left Ventricular Dysfunction - Pipeline by Amgen Inc., H1 2016
  • Left Ventricular Dysfunction - Pipeline by Bayer AG, H1 2016
  • Left Ventricular Dysfunction - Pipeline by Capricor Therapeutics, Inc., H1 2016
  • Left Ventricular Dysfunction - Pipeline by Innopharmax Inc., H1 2016
  • Left Ventricular Dysfunction - Pipeline by RedHill Biopharma Ltd., H1 2016
  • Left Ventricular Dysfunction - Pipeline by TiGenix NV, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Stage and Target, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Left Ventricular Dysfunction Therapeutics - Recent Pipeline Updates, H1 2016
  • Left Ventricular Dysfunction - Dormant Projects, H1 2016
  • Left Ventricular Dysfunction - Discontinued Products, H1 2016

List of Figures

  • Number of Products under Development for Left Ventricular Dysfunction, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Targets, H1 2016
  • Number of Products by Stage and Targets, H1 2016
  • Number of Products by Mechanism of Actions, H1 2016
  • Number of Products by Stage and Mechanism of Actions, H1 2016
  • Number of Products by Routes of Administration, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Molecule Types, H1 2016
  • Number of Products by Stage and Molecule Types, H1 2016
Back to Top